-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Celldex Therapeutics, Raises Price Target to $34

Benzinga·03/02/2026 17:11:07
Listen to the news
Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:CLDX) with a Neutral and raises the price target from $30 to $34.